Group 1 - The top three companies with the highest AH premium rates are Northeast Electric (00042) at 730.77%, Beijing Jingcheng Machinery Electric (00187) at 288.68%, and Sinopec Oilfield Service (01033) at 288.17% [1][2] - The bottom three companies with the lowest AH premium rates are CATL (03750) at -16.06%, WuXi AppTec (02359) at -7.28%, and China Merchants Bank (03968) at -4.68% [1][2] - The companies with the highest deviation values are Beijing Jingcheng Machinery Electric (00187) at 24.37%, Longpan Technology (02465) at 16.69%, and Cambridge Technology (06166) at 16.18% [1][3] Group 2 - The companies with the lowest deviation values are Northeast Electric (00042) at -85.40%, Junda Co., Ltd. (02865) at -56.63%, and Yangtze Optical Fibre and Cable (06869) at -52.47% [1][4] - The top ten AH stocks by premium rate include companies like Hongye Futures (03678) at 275.78% and Nanjing Panda Electronics (00553) at 237.14% [2] - The bottom ten AH stocks by premium rate include Weichai Power (02338) at -0.89% and Zijin Mining (02899) at 3.75% [2]

2025年四季度公募基金成绩单已出炉，"医药女神" 葛兰又一次站在了风口上。 葛兰能成为千亿顶流，一半是实力加持，一半是踩中了行业风口。 而中欧基金则借着她的东风，快速坐稳了主动权益赛道的头部位置，两人的崛起是一场互相成就。 事实上，和其他基金经理比，葛兰的专业底色足够硬。 她是国内医疗主题基金里少有的美国生物医学工程博士，懂医药研发、懂行业逻辑，这也是她能精准抓 住医药赛道机遇的关键。 数据显示，截至2025年年末，葛兰手里管的基金总规模缩减到了353.89亿元，比三季度少了81.55亿元； 而距离2021年千亿巅峰，已跌去750亿元，缩水幅度达68%。 此前，葛兰凭着年化超30%的收益封神，一举成为中欧基金顶流，被基民广泛熟知；如今，随着业绩持 续回调、规模不断缩水，质疑声越来越多。 当顶流的光环褪去，靠明星基金经理撑起的公募巨头，该怎么跳出 "一人衰、公司忧" 的怪圈？这不仅 是中欧的难题，更是整个公募行业都要面对的考验。 基金规模缩水近七成 2016到2021年，是葛兰的黄金五年，也是中欧基金借势起飞的五年。 那时候医药板块迎来牛市，尤其是创新药、医药研发生产外包（CXO）赛道，涨得一飞冲天，葛兰的 ...

Core Viewpoint - Nomura's report indicates that WuXi AppTec's revenue is expected to grow by 9.2% year-on-year to 11.7 billion yuan in Q4 2025, with net profit increasing by 142% to 7.1 billion yuan [1] Financial Projections - For the fiscal year 2026, revenue is projected to grow by 16% year-on-year to 52.6 billion yuan, surpassing market expectations of 51.1 billion yuan due to strong performance in the chemical business [1] - Net profit for 2026 is expected to increase by 3% year-on-year to 19.6 billion yuan [1] Business Segment Performance - By business segment, revenue for TIDES and late-stage development and manufacturing is expected to grow by 55% and 10% year-on-year, reaching 17.1 billion yuan and 21.6 billion yuan respectively [1] - The growth in TIDES is supported by sustained demand and the company's large-scale functional production capacity of 100,000 liters [1] Target Price Adjustments - Nomura has raised the target price for WuXi AppTec's H-shares from 132.8 HKD to 157.07 HKD and for A-shares from 120.85 CNY to 142.93 CNY, maintaining a "Buy" rating [1]

Company Situation - The company completed a general authorization placement of 58.4408 million new H-shares in January 2026, raising approximately HKD 1.319 billion, with a placement price of HKD 22.82, reflecting an 8.5% discount to the previous closing price. The funds are intended for laboratory and production facility construction, debt repayment, and working capital supplementation, which may impact the equity structure and short-term liquidity [2] Performance and Operating Conditions - The company announced on January 13, 2026, that it expects total revenue for 2025 to be between RMB 13.872 billion and RMB 14.24 billion, representing a year-on-year growth of 13% to 16%. However, the net profit attributable to the parent company is expected to decline by 6% to 10% year-on-year, primarily due to a decrease in non-recurring gains and losses. The net profit excluding non-recurring items is projected to increase by 36% to 41%, indicating an enhancement in the profitability of the main business [3] Industry and Risk Analysis - The CXO industry is experiencing intensified competition, with domestic leaders such as WuXi AppTec and Kelun Pharmaceutical, as well as international companies like Lonza, accelerating their market presence. This competitive landscape may exert pressure on the company's market share and pricing strategies. The company needs to address these challenges through capacity release and strategic acquisitions, such as the acquisition of Wuxi Bai'ao in November 2025 [4]

Market Overview - The Hong Kong stock market experienced a downward trend in the morning session, with the Hang Seng Index falling by 0.89% and the Hang Seng Tech Index declining by 1.68% [1] Sector Performance - The AI application sector showed strong performance, with notable gains: Zhiyun surged nearly 25%, MINIMAX-WP increased over 14%, and Kingsoft Cloud rose more than 4% [1] - The electric equipment sector continued its upward momentum, highlighted by Dongfang Electric rising over 11%, Harbin Electric increasing more than 7%, and Flat Glass Group gaining over 2% [1] - The optical communication sector was active, with Yangtze Optical Fiber and Cable rising over 11%, Huiju Technology increasing more than 7%, and Cambridge Technology gaining over 2% [1] - The pharmaceutical sector exhibited mixed results, with Reborn Bio rising by 13.65%, WuXi Biologics increasing by 4.83%, and Baidu's biotech unit rising by 3.88%, while three other companies saw declines [1] Capital Flow - Southbound capital saw a net inflow of nearly 2.8 billion HKD in the morning session [1]

A股市场今天（2月12日）整体小幅上涨，电力设备板块掀起涨停潮，成为上午A股市场板块主要亮点之一。 港股市场今天上午整体出现调整，恒生指数盘中一度跌破27000点。 股价大幅波动的港股方面，智谱大涨，盘中涨幅超过30%。消息面上，今天智谱上线并开源GLM-5。 A股电力设备板块掀起涨停潮 A股市场今天（2月12日）整体小幅上涨，创业板指涨幅超过1%。 主要行业板块和赛道方面，若按照申万一级行业划分，电力设备板块大涨，板块内个股掀起涨停潮，其中汉缆股份、中恒电气、望变电气、四方股份等多 股盘中涨停。消息面上，西门子能源股价持续走高，推高市场对该类赛道股票预期。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅▼ | 成交额 | | --- | --- | --- | --- | --- | --- | | 301217 | 铜量铜箔 | 36.53 | 4.50 | 14.05% | 25.78亿 | | 301120 | 新待电气 | 22.79 | 2.59 | 12.82% | 9.611Z | | 002498 | 汉绩股份 | 6.15 | 0.56 | 10.02% | 12.94亿 | | 00 ...

Core Insights - The main focus of the news is the significant inflow of capital into specific stocks, indicating strong investor interest and potential market trends. Group 1: Stock Performance and Capital Inflow - The top stock by capital inflow is Yingweike, with an inflow of 1.297 billion yuan and a price increase of 8.68% [1][2] - Leo Group follows with an inflow of 1.123 billion yuan and a price increase of 5.33% [1][2] - TBEA has an inflow of 545 million yuan and a price increase of 3.42% [1][2] - Western Materials shows an inflow of 504 million yuan with a price increase of 5.61% [1][2] - Tianfu Communication has an inflow of 462 million yuan and a notable price increase of 9.79% [1][2] Group 2: Sector Analysis - The stocks listed belong to various sectors, including specialized equipment, internet services, power grid equipment, and communication devices, indicating diverse investment interests [2][3] - The energy metals sector is represented by Shengtun Mining, which has an inflow of 395 million yuan and a price increase of 10.03% [1][2] - The healthcare sector is highlighted by WuXi AppTec, with an inflow of 389 million yuan and a price increase of 3.78% [1][2] Group 3: Additional Notable Stocks - Copper Crown Copper Foil has an inflow of 370 million yuan and a significant price increase of 11.36% [1][2] - Ningde Times, a key player in the battery sector, has an inflow of 334 million yuan with a price increase of 1.82% [1][2] - Other notable stocks include Yunnan Tin with an inflow of 288 million yuan and a price increase of 1.8% [1][3]

Core Viewpoint - The medical innovation sector is experiencing growth, highlighted by the successful debut of China's first fully self-developed orthopedic surgical robot, indicating advancements in medical technology and potential investment opportunities in the sector [1][2]. Group 1: Market Performance - As of February 12, 2026, the CSI Medical and Medical Device Innovation Index (931484) increased by 0.05%, with notable gains from companies such as WuXi AppTec (up 3.39%) and Kanglong Chemical (up 1.37%) [1]. - The Medical Innovation ETF (516820) is currently priced at 0.37 yuan, with a trading volume of 794.40 million yuan and a turnover rate of 0.42% [1]. - Over the past month, the average daily trading volume of the Medical Innovation ETF was 65.14 million yuan [1]. Group 2: Industry Insights - CITIC Securities believes that surgical robots represent one of the best business models in the medical device sector, as installed equipment will drive continuous consumption of consumables, leading to stable revenue and cash flow [2]. - The global market for surgical robots is estimated to exceed 1 trillion yuan, with significant growth potential in penetration rates and market size [2]. - Domestic leaders in the surgical robot market are accelerating product iterations, achieving performance levels close to global leaders, and have a substantial portion of their revenue from overseas markets, which are experiencing high growth [2]. - AI is expected to empower surgical robots to achieve autonomous operations, further assisting or replacing some surgical procedures performed by doctors, which will benefit industry penetration rates and enhance company valuations [2]. Group 3: Index Composition - The CSI Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability, growth potential, and research innovation capabilities, reflecting the overall performance of the medical and medical device sector [2]. - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, collectively accounting for 63.9% of the index [2].

Market Performance - The overall performance of A-shares shows an increase in the earnings forecast rate, with a pre-announcement rate of 37% for 2025, up from 33.6% in 2024[5] - As of February 6, 2026, 54% of A-share companies have disclosed their earnings forecasts for 2025, compared to 51.2% in 2024[5] Sector Insights - The semiconductor and CXO sectors are expected to show strong performance, with the semiconductor equipment sector outperforming materials and components[2] - The non-bank financial sector has a pre-announcement rate exceeding 50%, with a median profit growth rate of 76.1%, while the real estate sector shows a median profit decline of 18.5%[11] Consumer Market - The overall retail sales growth for 2025 is projected at 3.7%, with service consumption growing at 5.5%, outperforming goods retail growth of 3.8%[13] - During the 2026 Spring Festival, domestic flight bookings increased by approximately 15% compared to the previous year, indicating a strong recovery in travel demand[19] Healthcare Sector - The pharmaceutical and biotech sector shows a mixed recovery, with 10% of companies expected to turn profitable, while 49% are projected to incur losses[21] - Notable companies like WuXi AppTec are expected to see a net profit increase of 102.65% in 2025, reaching 19.15 billion yuan[25] High-end Manufacturing - The engineering machinery sector is experiencing a recovery, with excavator sales in January 2026 reaching 18,708 units, a year-on-year increase of 49.5%[28] - The domestic sales of excavators increased by 61.4%, indicating strong internal demand recovery[30]

Core Viewpoint - The report from Guosen Securities indicates that the medical services and consumer-related sectors have experienced long-term adjustments, resulting in valuations at historical lows. By 2026, improvements in supply structure, increased treatment volumes, and store optimization are expected to lead to a dual recovery in fundamentals and valuations, with AI empowerment providing new momentum for leading companies [1][2]. Group 1: Medical Services and Consumer Sectors - The medical services and consumer-related sectors are currently undervalued and poised for performance recovery, with a focus on specific sub-sectors [2]. - In medical services, improvements in supply structure and consumer environment are anticipated to gradually revive business, with stable customer spending and increased treatment volumes. Leading companies are expected to provide positive earnings guidance for 2026, indicating a potential dual recovery in fundamentals and valuations. AI-related business developments are also expected to drive new growth for leading medical service firms. Key companies to watch include Aier Eye Hospital (300015), Gushengtang, Tongce Medical (600763), and Haijia Medical [2]. - The pharmacy sector has shown significant marginal improvement in performance since Q3 2025, with leading companies improving same-store performance quarterly. Regulatory support from nine ministries emphasizes the long-term development direction of industry concentration and chain rate enhancement, with non-pharmaceutical adjustments and store structure optimization driving short-term performance improvements. Key companies include Yifeng Pharmacy (603939) and Dazhenglin (603233) [2]. Group 2: Home Medical Devices - The growth of home medical device companies is driven by increased product penetration and domestic production rates. Rapid growth is observed in products like Continuous Glucose Monitors (CGM) and sleep apnea machines, with leading domestic brands expanding internationally. Traditional categories like blood pressure monitors are increasingly focusing on the high-end market, with domestic brands steadily increasing market share. The combination of high domestic growth and new overseas markets is expected to contribute to sustained performance growth for home medical device companies. Key companies include Yuyue Medical (002223), Kefu Medical (301087), Sanofi Biological (300298), and Ruimaite (301367) [3]. Group 3: Innovative Drug Development - The collaboration for the international expansion of innovative drugs continues to deepen, with recent significant agreements between Shiyao Group and AstraZeneca, as well as Innovent Biologics and Eli Lilly. These collaborations highlight the growing recognition of China's innovative drug development capabilities by multinational pharmaceutical companies, showcasing the efficiency and cost advantages of Chinese innovative drugs [4]. Group 4: Investment Portfolio for 2026 - The investment portfolio for 2026 includes A-shares such as Mindray Medical (300760), United Imaging Healthcare, WuXi AppTec (603259), New Industry (300832), Meihua Medical (301363), Adebiotech (300685), Zhend Medical (603301), Yaokang Biological, Kingmed Diagnostics (603882), Aier Eye Hospital, Yuyue Medical, Yifeng Pharmacy, and Dazhenglin; H-shares include Kangfang Biologics, Kelun-Botai Biologics-B, Hutchison China MediTech, Kangnuo-B, Sanofi Biopharma, Gushengtang, and Aikang Medical [5].